Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Albumin-bound Paclitaxel in Recurrent/Persistent Cervical Cancer
NCT04188860Phase 2Completed
- Start
- Dec 2019
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in Cervical Cancer (CC). Primary endpoint: Overall Response Rate at 1 year. Started Dec 2019; status: completed.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04188860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188860.